[Impact of pretreatment variables on the outcome of standardized 131I therapy with 150 Gray in Graves' disease].
OBJECTIVE
We examined the impact of several pretreatment variables on thyroid size and function in 61 patients with Graves' disease one year after a standardized [131]I treatment with 150 Gray.


METHODS
FT3, FT4, and TSH serum concentrations were determined before and 1.5, 3, 6, and 12 months after therapy. Thyroid size was measured by ultrasound and scintigraphy before and one year after therapy.


RESULTS
One year after therapy, 30% of the patients had latent or manifest hyperthyroidism, 24% were euthyroid, and 46% had developed latent or manifest hypothyroidism. Age and initial thyroid volume were major predictors of post-therapeutical thyroid function. Thus, persistent hyperthyroidism was observed in 70% of the patients age 50 years and older with a thyroid size of more than 50 ml. With few exception, thyroid size markedly decreased after therapy. Initial thyroid size and age were also major predictors of posttherapeutical thyroid volume. Thyroid size normalized in all patients younger than 50 years of age, independent from initial thyroid size.


CONCLUSIONS
Radioiodine treatment with 150 Gray causes a considerable decrease in thyroid size in most patients with Graves' disease. Age and initial thyroid volume are important determinants of thyroid function and size after therapy and should be considered in dose calculation.
Pfeilschifter
J
J
Abteilung für Innere Medizin I, Medizinische Universitätsklinik, Deutschland.
Elser
H
H
Haufe
S
S
Ziegler
R
R
Georgi
P
P
D000328:Adult; D000367:Age Factors; D005260:Female; D005500:Follow-Up Studies; D006111:Graves Disease / Q000097:blood / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D011879:Radiotherapy Dosage; D013667:Technetium; D013960:Thyroid Function Tests; D013961:Thyroid Gland / Q000503:physiopathology; D013972:Thyrotropin / Q000097:blood*; D013974:Thyroxine / Q000097:blood*; D013997:Time Factors; D016896:Treatment Outcome; D014284:Triiodothyronine / Q000097:blood*
D007457:Iodine Radioisotopes; D014284:Triiodothyronine; D013667:Technetium; D013972:Thyrotropin; D013974:Thyroxine
Einfluss prätherapeutischer Variablen auf die Wirkung einer standardisierten 131J-Therapie mit 150 Gray beim Morbus Basedow.